China 
Africa 
Explore chapters and articles related to this topic
Rheumatic Disease
Published in John S. Axford, Chris A. O'Callaghan, Medicine for Finals and Beyond, 2023
Some symptoms are common in rheumatic diseases so pain, stiffness and joint swelling should be explored in depth. The important questions to ask a patient are listed in HISTORY & EXAMINATION 4.1.
Therapeutic Application of Monoclonal Antibodies in the Rheumatic Diseases
Published in Thomas F. Kresina, Monoclonal Antibodies, Cytokines, and Arthritis, 2020
Successful, longterm pharmacologic management of rheumatic diseases has been an elusive goal for physicians caring for individuals with these chronic disorders. Arguably, there has been no single major development in the field of rheumatologic therapeutics since the introduction of compound E in 1948 and its treatment of patients with rheumatoid arthritis (1). Over the past four decades, however, the quality of life in patients with rheumatic disease has been enhanced significantly as a result of many factors, including improved methods for earlier diagnosis, advances in the pharmacologic treatment of complications of rheumatic disease, recognition of the importance of optimizing functional outcomes, and acceptable management strategies for end-organ failure under some circumstances. In certain diseases, survival has also been prolonged. Nonetheless, there is mounting frustration among rheumatologists over the fundamental inability to alter or modify the natural course of most rheumatic disorders. This sentiment has been expressed most vocally in the area of rheumatoid arthritis (2–5). Longterm studies evaluating “second-line” or disease-modifying agents in this disorder have demonstrated relatively little improvement in outcome and a high degree of patient and physician dissatisfaction with currently available antirheumatic drugs. The development of safe and effective therapies capable of predictably modulating rheumatic disease expression for extendened periods is one of the most pressing issues in contemporary rheumatology.
Understanding the referring system for knee osteoarthritis patients from primary health care’s physician: A pilot study at Al-Ihsan hospital, Indonesia
Published in Ade Gafar Abdullah, Isma Widiaty, Cep Ubad Abdullah, Medical Technology and Environmental Health, 2020
Osteoarthritis causes chronic pain and disability and can affect the quality of life of patients. Bearing in mind the burden, the large epidemiology, and that the chronic pain it causes can decrease the quality of life, this rheumatic disease requires attention. Osteoarthritis (OA) constitutes the most frequent form of arthritis found in the community and is chronic, which has a big impact on public health (IRA, 2014).
JAK inhibitors in rheumatology
Published in Immunological Medicine, 2023
Rheumatology is a field in medicine that covers diseases presenting with painful musculoskeletal problems encompassed as rheumatic diseases. Therefore, rheumatic diseases overlap with other fields such as dermatology or gastroenterology which are also covered in a different section of this special issue. The pathophysiology involves autoimmunity and/or autoinflammation of unknown causes. Due to unknown etiology, specific treatment for a specific disease does not exist and glucocorticoid (GC) is still the primary treatment tool for most of the diseases. Unfortunately, aiming cure for rheumatic diseases is still not a realistic treatment goal. However, targeting specific molecules involved in the inflammatory process with biologics has revolutionized the treatment of rheumatic diseases which also lead to revolutionary change in other medical fields. The most recent advance in rheumatology is the efficacy of JAKis for rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) which demonstrated superiority over biologics. The convenience of an orally available JAKis as opposed to biologics that require parenteral injection is innovative from the patient’s perspective. Another aspect of JAKis that makes it unique is that the mechanism of action is conceptually selective to JAKs as an orally available small molecule compound however, very complex.
Antibodies against phosphorylcholine and protection against atherosclerosis, cardiovascular disease and chronic inflammation
Published in Expert Review of Clinical Immunology, 2022
Chronic inflammation is a common theme in several different diseases which together represent a huge part of disease burden today. The largest of these in terms of mortality is cardiovascular disease (CVD), including myocardial infarction (MI) and stroke. The major underlying factor is atherosclerosis, which is the main topic herein, not only because CVD and atherosclerosis are dominant as disease causes, but also because much more is known about phosphorylcholine (PC) and antibodies against PC (anti-PC) in these conditions as compared to other chronic inflammatory conditions. Among these, rheumatic diseases are typically of inflammatory and also chronic inflammatory nature and nowadays also osteoarthritis is usually seen as an inflammatory and rheumatic condition. In addition, type 2 diabetes and insulin resistance and even dementia and obesity are examples of chronic inflammation[1].
Experiences of foot health in patients with rheumatoid arthritis: a qualitative study
Published in Disability and Rehabilitation, 2022
Anne-Marie Laitinen, Carina Boström, Sasu Hyytiä, Minna Stolt
Most of the participants were female (n = 18). The median age was 68 years (mean 64, range 24–83, SD 13). The participants’ basic level of education was either elementary school (n = 15) or high school (n = 5). Their professional level of education was mostly short vocational education (n = 6) or secondary vocational education (n = 6). Some participants had a degree from a university of applied sciences (n = 2) or an academic university (n = 2). Two participants had no professional education. Most of the participants were retired, but one was an employed and other was an entrepreneur. Most of them had been diagnosed with RA (n = 13) or juvenile RA (n = 7). In addition, some participants reported other diagnosed rheumatic diseases: osteoporosis (n = 5), osteoarthritis (n = 3), fibromyalgia (n = 2), psoriatic arthritis (n = 1) and Sjögren’s syndrome (n = 1).